Daniel Gilbert, DO
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (45.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 41.2% of the total. Reporting peaked in 2019 at $4,733 and has fallen 70.3% since, to $1,407 in 2025.
Across 171 payments — averaging $67.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Johnson & Johnson$3K
- Boston Scientific$797
- AbbVie$577
- Ferring Pharmaceuticals Inc.$316
- Neotract Inc.$265
- plus $2K from 29 others
What the payments were for
- Consulting fees$2,34120%
- Speaking & faculty fees$2,80024%
- Travel & lodging$1,0119%
- Food & beverage$5,28446%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 29 | $4,754 |
| Johnson & Johnson(2 entities) | 6 | $2,547 |
| Boston Scientific | 14 | $797 |
| AbbVie(2 entities) | 31 | $577 |
| Ferring Pharmaceuticals Inc. | 8 | $316 |
| Neotract Inc. | 9 | $265 |
| Calyxo, Inc. | 3 | $224 |
| Caldera Medical, Inc | 3 | $191 |
| Olympus America Inc. | 3 | $187 |
| Bayer | 4 | $173 |
| Progenics Pharmaceuticals, Inc. | 6 | $157 |
| Pfizer | 6 | $125 |
| Urogen Pharma, Inc. | 3 | $119 |
| Endo Pharmaceuticals Inc. | 2 | $115 |
| Coloplast | 4 | $93 |
| Telix Pharmaceuticals | 4 | $84 |
| Medtronic | 3 | $78 |
| Astellas Pharma US Inc | 5 | $76 |
| Agiliti Surgical, Inc. | 1 | $70 |
| Dendreon Pharmaceuticals LLC | 3 | $68 |
| Endo USA, Inc. | 4 | $68 |
| Teleflex LLC | 3 | $66 |
| Laborie Medical Technologies Corp. | 2 | $66 |
| Tolmar, Inc. | 2 | $39 |
| Novartis | 2 | $37 |
| Bioprotect Medical, Inc. | 2 | $33 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $32 |
| Bard Access Systems, Inc. | 1 | $30 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Koelis Inc. | 1 | $24 |
| 180 Medical, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| Immunitybio, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,957
- ADSTILADRIN$155
- AMS 700 CXR RTE KIT$145
- Xofigo$142
- iTIND System$141
- UroLift$122
How this compares
$11,536 in reported general payments places this provider in the 80th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 31 | $19,089 |
| Solifenacin Succinate | 67 | $6,801 |
| Potassium Citrate ErPotassium Citrate | 25 | $3,624 |
| Estradiol | 66 | $3,400 |
| Tamsulosin Hcl | 138 | $2,027 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 66 | $1,090 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $848 |
| Finasteride | 42 | $510 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $116 |
| Ciprofloxacin Hcl | 35 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $76 | $19,08931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 269 urology providers in Arizona.
Other urology in Mesa
- Rahul MehanMesa$277K
- Shoaib SafiullahMesa$14K
- Greggory PeiferMesa$14K
- Harpreet WadhwaMesa$14K
- John WilliamsMesa$11K
- Kashif AlviMesa$11K
- Raul WebsterMesa$10K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.